尊龙Z6官方网站

On November 8, 2024, Abbisko Therapeutics (HKEX: 02256) today announced it will present preliminary phase 2 study results of its independently developed CSF-1R inhibitor, pimicotinib (ABSK021), at the 66th ASH Annual Conference taking place from December 7-10, 2024 in San Diego, California. The study investigated the use of pimicotinib in patients with chronic graft-versus-host disease (cGvHD) who have not responded to one or more prior lines of therapy. 

Abbisko's presentation at the ASH conference:

Publication Number: 99

Title：A Phase II Study to Evaluate the Efficacy and Safety of Pimicotinib (ABSK021) in Chronic Graft Versus Host Disease (cGvHD) after 1 or More Lines of Systemic Treatment

Presentation Time：10:00AM

Session Date: Saturday, December 7, 2024

About cGvHD

Chronic graft-versus-host disease (cGvHD) is a clinicopathological syndrome, including classical cGvHD and overlap syndrome, that occurs when donor lymphocytes attack the recipient's organs during the reestablishment of immunity following allogeneic hematopoietic stem cell transplantation (HSCT). It is considered one of the major complications associated with this procedure. According to Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease（2024）, cGvHD affects 30 to 70% of patients who have undergone allogeneic HSCT ^{[1] [2]}.

The clinical manifestations of cGvHD are diverse with great individual differences, and the course of cGvHD is long-lasting. Multiple vital organs can become involved, thereby seriously affecting the quality of life and long-term survival of patients. 

References: 

1. Xu L, Chen H, Chen J, et al. The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China recommendations from the Chinese Society of Hematology. J Hematol Oncol, 2018, 11（1）: 33. DOI: 10.1186/s13045- 018- 0564-x

2. HSCA Group 2024. Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):713-726. DOI: 10.3760/cma.j.cn121090-20240611-00217.